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Human Human/faeces MN203697 Campylobacter concisus ATCC 33237 (97.86%) ATCC: American type culture collection rising reports of Toxoplasma-related neurological disorders are also concerning. [11] The burden of diseases attributable to toxoplasmosis is probably greater than currently suggested, [12] and seroprevalence data from different patient groups could help in the formulation of targeted health policies. Thus, we analysed Toxoplasma seroprevalence in various patient groups at our tertiary care hospital over more than a decade.
materIals and methods

Study site
The study was conducted at the Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India, a tertiary care hospital catering to a population of seven neighbouring states, namely Punjab, Haryana, Himachal Pradesh, Uttar Pradesh, Uttarakhand, Jammu and Kashmir and Rajasthan.
Study population
The study was approved by the Institute Ethics Committee of PGIMER, Chandigarh (Reference number: NK/5136/Res). Inclusion criteria: All patients samples received in the Medical Parasitology-Serology Laboratory of PGIMER, Chandigarh, India, from January 2004 to October 2014 for Toxoplasma serology were included for the analysis. This included samples from patients with clinical suspicion of toxoplasmosis and those undergoing routine screening (antenatal and transplant donors). Exclusion criteria: All samples haemolysed, improperly labelled, leaking or of inadequate quantity were excluded. The patient details and results of Toxoplasma serology performed throughout the study period were analysed. Amongst a total of 8397 included patients, 6633 patients were clinically suspected of toxoplasmosis and 1764 were subjected to routine screening for antibodies against T. gondii. The patients with clinically suspected toxoplasmosis (n=6633) were further categorized as: congenital toxoplasmosis (n = 2000), neurological toxoplasmosis (n = 287), ocular toxoplasmosis (n = 104), toxoplasmosis in immunocompromised patients and the remaining patients who could not be assigned any clinical category were grouped according to age as paediatric (n = 1946) and adult toxoplasmosis (n = 817). Immunocompromised patients with toxoplasmosis comprised of patients with HIV/ AIDS (n = 1409) and post-transplant recipients (n = 70), which included haematopoietic stem cell transplant [HSCT] [n = 64], liver transplant [n = 4] and renal transplant [n = 2] recipients. A total of 1764 samples were subjected to routine screening which included antenatal screening (n = 1741) and transplant donor screening (n = 23) cases. All patients were categorised age wise into neonates (<1 month), infants (>1 month-1 year), 1-5 years, 6-12 years, 13-18 years, 19-30 years, 31-40 years, 41-50 years, 51-60 years, 61-70 years, 71-80 years and 81-90 years for the analysis. A flow diagram depicting the study design is shown in Figure 1 .
Sample collection
For the detection of anti-T. gondii antibodies, blood was aseptically collected by venipuncture in sterile plain vials. The blood was allowed to clot, and following clot retraction, the serum sample was separated and stored at −20°C till further analysis.
Laboratory procedures
All samples were subjected to the in-house enzyme-linked immunosorbent assay (ELISA) for the detection of anti-T. gondii IgG and IgM antibodies as previously reported in the protocol. [3] Briefly, the antigen was prepared from the RH strain of T. gondii tachyzoites harvested from the peritoneal cavity of Swiss albino mice after 3 days of infection. The tachyzoites were purified by differential centrifugation, kept overnight at 4°C and then subjected to sonication and cold centrifugation. Toxoplasma antigen (1 µg/well) was coated on microtitre plates, and ELISA was performed as described previously.
Statistical analysis
The statistical analysis was done using SPSS software version 19.0 (SPSS South Asia Pvt. Ltd., Bangalore, Karnataka, India).
results
Toxoplasma seropositivity from 2004 to 2014
Of the 8397 samples received for Toxoplasma serology, 4400 (52.4%) were from male and 3997 (47.6%) from female patients. An overall seropositivity of 21% (n = 1763/8397) was recorded, with IgG positivity in 5.7% (n = 481/8397) and IgM positivity in 15.3% (n = 1282/8397) patients. Amongst IgM seropositive cases, 28.7% (n = 368/1282) were also IgG positive, whereas 71.3% (n = 914/1282) were IgG negative. The percentage Toxoplasma seroprevalence over the 10-year study duration is depicted in Figure 2a . The seroprevalence ranged from 16.4% to 31.7% from 2004 to 2012, whereas a drop to 9.7% and 8.1% was noted in 2013 and 2014, respectively.
Age-wise Toxoplasma seroprevalence
With increasing age, a statistically significant increase in overall seropositivity was observed, though there were fluctuations in the intervening years, with the lowest seropositivity in infants (4.9%, n = 73/1480). The highest seropositivity was seen in the 81-90 years' age group (80%, n = 4/5) which included 3 cases of HIV related and one case of neurological toxoplasmosis. Amongst all 1763 samples with positive Toxoplasma serology, the majority belonged to patients in the 19-30 years' age group (47.4%, n = 836), followed by 31-40 years (16.0%, n = 282). Similarly, amongst all 1282 patients with IgM seropositivity, the majority were present in the 19-30 years' age group (53%, n = 680), followed by 31-40 years' age group (n = 198, 15.4%) . Majority of the Toxoplasma IgG-seropositive cases were noted in the 19-30 years' age group (32.4%, n = 156/481), followed by 6-12 years (7.7%, n = 37/481) and >1-5 years' age group (5.6%, n = 27/481). Amongst all age groups, IgM seropositivity was higher than IgG seropositivity except for the extremes of ages including neonates (11.4% vs. 2.7%) and elderly of 71-80 years (25% vs. 20%) and 81-90 years (60% vs. 20%) [ Figure 2b and Table 1 ].
Gender-wise Toxoplasma seroprevalence
A higher Toxoplasma seropositivity was observed in females at 29.5% (n = 1179/3997) compared to males at 13.3% (n = 584/4400). IgM seropositivity was also higher in females versus males at 24% (n = 959) versus 7.3% (n = 323) males, whereas IgG seropositivity was similar across both genders at 5.5% in females (n = 220) and 5.9% in males (n = 261). Across age groups years 19-30 (P = 0.032), 31-40 (P < 0.001) and 41-50 (P = 0.001), a higher seropositivity was revealed amongst female neonates (P = 0.036), as shown in Table 1 .
Toxoplasma seroprevalence in different clinical categories
In patients with clinically suspected toxoplasmosis, the seroprevalence was highest in cases of ocular toxoplasmosis (n = 47/104, 47.2%), followed by neurological toxoplasmosis (n = 77/287, 26.8%), toxoplasmosis in HIV/AIDS (n = 267/1409, 18.9%), toxoplasmosis in post-transplant recipients (n = 12/70, 17.1%) and patients with congenital toxoplasmosis (n = 144/2000, 7.2%). Amongst other cases, adult toxoplasmosis (n = 252/817, 30.8%) showed a higher seroprevalence compared to of paediatric cases (n = 172/1946, 8.8%) [ Table 2 ]. In patients subjected to Toxoplasma screening, the IgM seropositivity was observed to be maximum in transplant donor screening (n = 10/23, 43.5%), followed by antenatal screening (n = 674/1741, 38.7%), ocular (n = 28/104, 26.9%) and adult toxoplasmosis (n = 170/817, 20.8%), whereas the highest IgG seropositivity rate was observed in patients with ocular toxoplasmosis (n = 19/104, 18.3%), followed by neurological (n = 35/287, 12.2%), adult (n = 82/817, 10%) and
HIV/AIDS-associated toxoplasmosis (n = 131/1409, 9.3%) [ Figure 2c ]. A decline in seroprevalence from 2004 to 2014 was noted in HIV/AIDS patients and antenatal screening group.
dIscussIon
Since toxoplasmosis seroprevalence varies with patient demographics and regional socioeconomic parameters, an awareness of the seroprevalence trends in different patient groups provides insights for framing targeted public health policies. We observed an overall seroprevalence of 21% with anti-Toxoplasma IgG in 5.7% and IgM in 15.3% of patients at our hospital in North India. Another recent study from North India evaluating anti-Toxoplasma IgG and IgM antibodies in women of reproductive age group reported a prevalence of 22.4% and 1.4%, respectively. [13] Studies from North India have documented an anti-Toxoplasma IgG seroprevalence of 15%-51.8% and 2%-5% for IgM antibodies. [2] [3] [4] Globally, approximately 25%-30% of humans are infected with T. gondii; however, the seroprevalence varies greatly between different countries (10%-80%) and even within countries. [14] This is perhaps due to the differences in exposure to the organism according to the socioeconomic status, cultural beliefs and anthropogenic factors such as handling and owning cats, consumption of meat and unwashed fruits and vegetables, handling soil and variations in hand hygiene practices. [15] Other factors such as climate which affects the survival of oocysts in the environment, sanitation and quality of water supply can also impact the seroprevalence trends. [16] The Toxoplasma seroprevalence in our study revealed a decline from 28.0% in 2004 to 8.1% in 2014, the exact reasons of which need to be explored. It is plausible that an improvement in socioeconomic status, water and food sanitation, better regulation of indigenous, imported meat quality, avoidance of risk factors during pregnancy and increasing awareness of toxoplasmosis amongst patients and doctors could all have contributed to this. A study from Poland investigating the prevalence of anti-Toxoplasma IgG between 1998 and 2003 reported a decline in seroprevalence from 45.4% to 39.4%. [17] The authors of the study attributed this to improvements in T. gondii infection prevention over the years. A decline in maternal seroprevalence from 53% to 20% and a 85% decrease in the incidence of congenital toxoplasmosis over time have also been seen in Switzerland from 1982 to 2015. [18] The relationship between increased prevalence of Toxoplasma and age has been previously documented in various studies. [13, 19, 20] However, most of the studies have been carried out in women of childbearing age. We observed a rising seroprevalence of Toxoplasma across all ages in both men and women, with the highest percentage seropositivity amongst the elderly at 45%-80% in the 60-90 years' age group. From Germany, Wilking et al. 2016 also reported that Toxoplasma seroprevalence increased from 20% in the 18-29 years' age group to 77% in the 70-79 years' age group in both genders. [15] We noted that IgG seropositivity was higher in the extremes of age possibly due to transfer of maternal IgG antibodies in neonates and persisting IgG antibodies in the elderly population.
A higher seroprevalence amongst females, particularly in the fertile age group of 19-50 years, was seen, although a higher seroprevalence with age was not evident. Toxoplasma-specific IgG seroprevalence amongst women and the infection pressure, or probability of exposure to T. gondii, have been reported to increase with age in previous studies. [12, 13] The seroprevalence of Toxoplasma amongst suspected congenital toxoplasmosis cases was 7.2% in our study. Congenital toxoplasmosis can result in abortion or lead to severe visual and neurological malformation in the foetus such as hydrocephalus, cerebral calcification and/or chorioretinitis. [21, 22] In France, early detection of seroconversion in pregnant women, frequent re-testing using highly sensitive polymerase chain reaction, followed by early treatment in the national program, has been associated with a lower rate of severe congenital toxoplasmosis. [21] Recent reports of high prevalence of congenital toxoplasmosis (28%) from Brazil, suggest that screening programs could be beneficial in such regions. [23] There is a low-to-moderate prevalence of Toxoplasma infection reported in India amongst antenatal women ranging from 15% to 49.5% [3, 24] and was also observed to be 44.9% in our study. A low seroprevalence (10%-30%) is reported from developed regions such as North America, northern Europe and Japan, whereas a moderate seroprevalence (30%-50%) has been reported from central and southern Europe, and high seroprevalence (>50%) has been found in Latin America and African countries. [23] Routine antenatal screening is practised at our tertiary care centre; however, it is not a norm at the rural primary healthcare centres and other district-based hospitals of the country, and a higher prevalence of pregnancy-associated toxoplasmosis can be expected in the community.
Amongst other clinical categories of patients, the highest seropositivity was observed in patients with suspected ocular toxoplasmosis. Although congenital infections commonly cause retinochoroiditis, most cases of ocular toxoplasmosis are acquired after birth, and it is an important cause of visual impairment. [15] A prevalence of Toxoplasma ranging from 4.2% to 8.4% has been described in cases of uveitis in various studies; [14] however, most studies have used molecular tests for defining cases. Toxoplasmosis serology is useful to confirm active toxoplasmosis retinochoroiditis and supports clinical diagnosis in up to 96% of cases. [22] In 80% of the immunocompetent patients, no clinical signs of toxoplasmosis are apparent; therefore, assessing the serological status is essential in cases at high risk for more severe disease forms such as ocular toxoplasmosis. [22] The incidence of opportunist toxoplasmosis is probably underestimated, poorly studied and depends on the seroprevalence of infection amongst the general population. It carries the risk of complications in HIV/AIDS patients and recipients of HSCT or SOT, wherein Toxoplasma-naïve patients are at a higher risk of acute, severe and lethal toxoplasmosis, whereas patients with latent infection are at a risk of reactivation and secondary dissemination. We observed an 18.9% seroprevalence of Toxoplasma amongst HIV/AIDS patients and 17.1% in post-transplant recipients. Serology is often limited due to immune deficiency impacting antibody production, making molecular detection of parasite the most sensitive test in these settings. [25] Pre-transplant screening of donors and recipients also revealed a high seroprevalence (47.8%). However, the true burden of toxoplasmosis in this patient group can only be estimated by screening paired pre-and post-transplant samples from both donors and recipients. Since this was not performed in the present study, future studies must be undertaken to elucidate the same. In addition, a decline in seroprevalence was noted from 2004 to 2014 amongst antenatal cases (48.7% vs. 19.7%) and HIV/AIDS patients (22.2% vs. 4.7%), the reasons of which are not clear, but could be indicative of improvements in T. gondii infection prevention in HIV/AIDS patients and better awareness amongst physicians regarding antenatal screening and management of toxoplasmosis in these patient groups. In a recent study examining HIV-infected military personnel screened for T. gondii IgG antibody in the USA over 30 years, a decline in seroprevalence was observed which the authors suggested was due to a possible decreased exposure to the infectious agent as a result of ongoing public health education, improved hygiene and general improvements related to meat preparation and handling of soil and cat faeces. [25] Unfortunately, in our study, some patient details such as contact with pets, feeding habits, history of previous medication and blood transfusions were not available, and thus, the factors affecting seroprevalence could not be studied.
conclusIon
The epidemiology of toxoplasmosis is complex and involves many variables. To adequately understand the factors associated with this infection further studies in seropositive individuals with focus on risk assessment are required. The
